CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Enzalutamide PillWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

NCT04475601 COVID-19 Corona Virus Infection Drug: Enzalutamide Pill
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Clinical worsening to invasive mechanical ventilation or death as assessed by the 7-point ordinal scale

Measure: Time to worsening of disease

Time: Up to 30 days after inclusion

Description: Time to discharge from hospital assessed by the 7-point ordinal scale

Measure: Time to improvement of disease

Time: Up to 30 days after inclusion

Secondary Outcomes

Description: Safety evaluation, as measured by AEs

Measure: Adverse events

Time: Up to 6 months

Description: Total days of extra oxygen

Measure: Duration of supplemental oxygen (days)

Time: Up to 30 days

Description: Frequence of admission to ICU

Measure: Admission to ICU

Time: Up to 30 days and up to 6 months

Description: Changes of laboratory parameters: Hb

Measure: Laboratory assessment of Hemoglobin concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: PCR based SARS-CoV-2 measurement from upper respiratory tract

Measure: Virus load assessment day 0, 2, 4 and 6

Time: UP to 7 days

Description: Total number of days evaluated at 30 days and 6 months

Measure: Hospital stay (days)

Time: Up to30 days and 6 months

Description: If admitted to hospital due to COVID-19 disease after discharge from hospital

Measure: Re-admission to hospital due to rebound COVID-19

Time: Evaluated for 30 days and after 6 months

Description: Death due to any cause

Measure: Mortality at 6 months

Time: up to 30 days and up to 6 months respectively

Description: Testosterone and estrogen levels

Measure: Hormonal status at 6 months

Time: from baseline to 6 months

Description: Identification of serologic immunity based after 6 months from inclusion

Measure: Serological immunity for COVID-19

Time: At 6 months

Description: Changes of laboratory parameters: CRP

Measure: Laboratory assessment of CRP concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: ALAT, ASTA and/or ALP

Measure: Laboratory assessment of liver function day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: Createnin

Measure: Laboratory assessment of creatinine concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: D-dimer

Measure: Laboratory assessment of D-dimer concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: TPK

Measure: Laboratory assessment of platelets concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: IL-6

Measure: Laboratory assessment of IL-6 concentration day 0, 2, 4 and 6

Time: Up to 30 days

Description: Changes of laboratory parameters: Differentiate count of leucocytes

Measure: Laboratory assessment of B- and T-lyphocytes concentration day 0, 2, 4 and 6

Time: Up to 30 days

No related HPO nodes (Using clinical trials)